Table 4.
FEUA0–24 h and CLUR0–24 in Japanese and non-Asian subjects following single and multiple doses
| Treatment | FEUA0–24, %
|
CLUR0–24, mL/min
|
||||
|---|---|---|---|---|---|---|
| Single dose, fasted | Single dose, fed | Multiple dose, fed | Single dose, fasted | Single dose, fed | Multiple dose, fed | |
| Japanese subjects | ||||||
| Baseline | 6.81 (5.29–8.32) | 6.46 (5.55–7.36) | 6.46 (5.55–7.36) | 8.67 (6.74–10.6) | 7.68 (5.71–9.65) | 7.68 (5.71–9.65) |
| Placebo | 6.09 (4.59–7.59) | 6.75 (5.49–8.00) | 6.24 (5.33–7.15) | 6.70 (4.86–8.53) | 8.23 (6.76–9.70) | 8.92 (6.91–10.9) |
| Verinurad 2.5 mg | 7.72 (6.01–9.43) | 7.75 (6.80–8.70) | 7.57 (6.74–8.41) | 7.82 (6.90–8.74) | 11.4 (9.74–13.0) | 12.2 (10.3–14.2) |
| Verinurad 5 mg | 9.05 (7.20–10.9) | 11.2 (7.42–14.9) | 14.5 (9.93–19.1) | 10.9 (8.88–12.9) | 16.0 (11.7–20.3) | 13.7 (9.35–18.1) |
| Verinurad 10 mg | 10.8 (7.87–13.6) | 20.5 (11.3–29.6) | 13.7 (10.8–16.6) | 14.3 (10.7–17.9) | 16.0 (9.88–22.1) | 19.7 (16.7–22.7) |
| Verinurad 15 mg | 14.5 (7.08–22.0) | 9.61 (2.96–16.3) | 16.0 (10.7–21.2) | 15.0 (6.40–23.6) | 12.1 (4.04–20.2) | 23.9 (14.9–32.9) |
| Non-Asian subjects | ||||||
| Verinurad 10 mg | 10.4 (4.84–16.0) | 11.7 (6.44–17.0) | 13.2 (8.45–17.9) | 15.3 (7.35–23.3) | 18.6 (8.95–28.2) | 20.6 (13.7–27.4) |
Note: Data are mean (95% CI).
Abbreviations: FEUA0–24, fractional excretion of uric acid from time 0 to 24 hours; CLUR0–24, renal clearance of uric acid from time 0 to 24 hours.